GSK PLC Sponsored ADR $GSK Stock: Foster Victor Wealth Advisors LLC Raises Stake

Key Points

• Foster Victor Wealth Advisors increased its GSK stake by 5.8% in the third quarter, adding 23,934 shares to hold 438,220 shares valued at approximately $21.7 million. Institutional investors collectively own 15.74% of the company.
• Analyst sentiment remains mixed, with four Buy, twelve Hold and three Sell ratings; the consensus rating is Hold with a $55.33 price target versus a recent share price of $50.09.
• GSK exceeded quarterly earnings and revenue expectations, while raising its quarterly dividend to $0.4515 per share, equivalent to an annualized $1.81 payout and a 3.6% yield.

Foster Victor Wealth Advisors LLC grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 5.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 438,220 shares of the pharmaceutical company's stock after purchasing an additional 23,934 shares during the quarter. GSK comprises about 1.0% of Foster Victor Wealth Advisors LLC's investment portfolio, making the stock its 24th largest position. Foster Victor Wealth Advisors LLC's holdings in GSK were worth $21,674,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in GSK. Bogart Wealth LLC increased its stake in shares of GSK by 15.3% in the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock valued at $83,000 after buying an additional 200 shares in the last quarter. Natural Investments LLC raised its holdings in shares of GSK by 2.8% in the second quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company's stock valued at $405,000 after buying an additional 211 shares during the last quarter. Grove Bank & Trust raised its holdings in shares of GSK by 3.8% in the third quarter. Grove Bank & Trust now owns 5,859 shares of the pharmaceutical company's stock valued at $282,000 after buying an additional 215 shares during the last quarter. Canandaigua National Bank & Trust Co. lifted its position in GSK by 3.7% during the 3rd quarter. Canandaigua National Bank & Trust Co. now owns 6,185 shares of the pharmaceutical company's stock worth $298,000 after buying an additional 223 shares in the last quarter. Finally, Focused Alpha LLC lifted its position in GSK by 3.7% during the 3rd quarter. Focused Alpha LLC now owns 6,764 shares of the pharmaceutical company's stock worth $326,000 after buying an additional 242 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on GSK shares. Berenberg Bank reissued a "buy" rating on shares of GSK in a report on Tuesday, October 6th. Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday, September 8th. They issued a "sector perform" rating for the company. Weiss Ratings downgraded shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Jefferies Financial Group reiterated a "buy" rating on shares of GSK in a research report on Monday, September 28th. Finally, The Goldman Sachs Group reissued a "neutral" rating on shares of GSK in a research note on Monday, June 29th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $55.33.

GSK Stock Down 1.1%

NYSE GSK opened at $50.09 on Thursday. The stock has a market capitalization of $101.31 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of 2.28 and a beta of 0.33. GSK PLC Sponsored ADR has a 52 week low of $42.85 and a 52 week high of $61.69. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The stock has a fifty day moving average of $49.55 and a 200-day moving average of $51.49.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.78 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a dividend of $0.4515 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.81 annualized dividend and a yield of 3.6%. This is an increase from GSK's previous quarterly dividend of $0.44. GSK's dividend payout ratio (DPR) is presently 55.31%.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Hibsago for adults with chronic hepatitis B without cirrhosis. The treatment is described as the first potential “functional cure,” offering some patients the possibility of stopping long-term therapy and creating a significant new commercial opportunity. US FDA approves GSK's hepatitis B drug
• Positive Sentiment: Jefferies reiterated its Buy rating and 2,500p price target, citing the Hibsago approval and maintaining a potential annual sales forecast of approximately £2.2 billion. This supports the view that the drug could become an important long-term growth driver. GSK hepatitis B drug approval supports £2.2bn sales forecast
• Positive Sentiment: GSK’s Jemperli received U.S. approvals, including accelerated approval for advanced rectal cancer and recognition as the first approved immunotherapy for certain locally advanced kidney cancers. The expanded indications could broaden Jemperli’s revenue base. GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
• Positive Sentiment: GSK completed its exclusive licensing agreement with HUTCHMED for a KRAS-EGFR antibody-drug conjugate outside China and also announced a strategic partnership involving Mubadala Bio’s IDS, supporting efforts to expand its oncology pipeline and external innovation. HUTCHMED Announces Closing of KRAS-EGFR License to GSK
• Neutral Sentiment: Analysts expect GSK to report quarterly earnings shortly. One preview warns of a possible year-over-year earnings decline and suggests the company may lack the typical factors associated with a likely earnings beat, creating a near-term event risk. Analysts Estimate GSK to Report a Decline in Earnings
• Negative Sentiment: CSL selected GSK executive Deborah Waterhouse as its next CEO. Her departure may raise concerns about management continuity, although it does not change GSK’s operating outlook directly. CSL taps GSK’s Deborah Waterhouse as CEO

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.